PUBLISHER: IMARC | PRODUCT CODE: 2024757
PUBLISHER: IMARC | PRODUCT CODE: 2024757
The global hernia mesh devices market size reached USD 2.1 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 2.7 Billion by 2034, exhibiting a growth rate (CAGR) of 2.65% during 2026-2034. The increasing number of hospitals, clinics, and ambulatory surgical centers is stimulating the market.
Rising Preference for Laparoscopic Procedures
Laparoscopic hernia repair usually involves the use of a camera and small incisions to guide the placement of the mesh. This, in turn, results in quicker recovery times, less postoperative pain, and reduced hospital stays compared to traditional open surgery. In April 2024, one of the medical technology companies, TELA Bio, announced the commercial launch of OviTex inguinal hernia repair (IHR) reinforced tissue matrix, a product tailored for laparoscopic and robotic-assisted procedures, in the U.S. It offers flexibility for surgeons based on patient needs and procedural preferences.
Expanding Adoption of Robotic-Assisted Surgery
The inflating need for improving the accuracy of mesh placement, more complex maneuvers, and minimizing the risk of complications is catalyzing the market. Robotic-assisted surgery also offers benefits, such as reduced blood loss, smaller incisions, and quicker recovery times, for patients. In May 2024, Medtronic initiated additional clinical studies of its Hugo robotic-assisted surgery system to expand its indications to hernia and gynecology. This is bolstering the hernia mesh devices market outlook report.
Increasing Focus on Patient-Specific Solutions
Numerous advancements in imaging technologies and computer modeling, which enable precise preoperative planning and customized mesh designs, are catalyzing the market. Patient-specific solutions aim to minimize complications, enhance the success rates of hernia repairs, and improve overall patient satisfaction. In January 2024, Absolutions received an FDA breakthrough designation for an abdominal wall closure device to reduce the risk of hernia by distributing suture tension over a large area of tissue.
Inguinal hernia dominates the hernia mesh devices market outlook
An inguinal hernia occurs when a portion of the intestine protrudes through a weakened spot in the abdominal muscles. Addressing this common condition, several companies have recently launched innovative products. For example, Medtronic introduced the Parietex Hybrid Mesh, which combines non-absorbable and absorbable components to enhance biocompatibility and tissue integration.
Synthetic mesh currently holds most of the total hernia mesh devices market share
Synthetic mesh devices represent medical implants made from materials like polypropylene, designed to provide support to weakened or damaged tissue. Bard unveiled the Ventralight ST Mesh, featuring a lightweight, large-pore design with a bioresorbable coating that promotes better tissue integration.
Hospitals hold the majority of the global hernia mesh devices market demand
Hernia mesh devices are medical implants used in hospitals to repair hernias by providing additional support to weakened or damaged tissue. Becton, Dickinson, and Company developed an optilene mesh that is engineered to reduce the risk of adhesion and infection while providing robust support for tissue regeneration.
North America exhibits a clear dominance in the market
The hernia mesh devices market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.
As per the hernia mesh devices market analysis report, North America exhibits a clear dominance in the market, driven by advancements in surgical techniques, growing incidences of hernias, and a strong focus on improving patient outcomes. In January 2024, TELA Bio Inc., a commercial-stage medical technology company, introduced LIQUIFIX precision and LIQUIFIX FIX8 laparoscopic open hernia mesh fixation devices in the U.S. Both devices are the only FDA-approved devices that affix mesh and approximate peritoneal tissue with liquid anchors.
The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major market companies have also been provided. Some of the key players in the market include: